Notice of Proposed Sale · 144

Rapport Therapeutics, Inc.

RAPPNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 24, 2026Accepted Aug 24, 2026, 4:28 PM EDTFiling CIK 2022156Accession 0001950047-26-008594

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Rapport Therapeutics, Inc.
Issuer CIK: 0002012593
SEC file number: 001-42121
Phone: 8573218020
Person for whose account securities are to be sold: KRISHNASWAMY YELESWARAM
Relationships to issuer: Officer
Street: 99 High Street, Suite 2100
City: Boston
State / country code: MA
Postal code: 02110

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	11,472	553,409.28	47,978,286	08/24/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	06/09/2024	Founders Shares	Issuer	11,472	N	06/09/2024	N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
10b5-1 Sales for KRISHNASWAMY YELESWARAM	Common	08/19/2026	404	20,159.60

Seller — prior-sale row 1, entry 1

Name: 10b5-1 Sales for KRISHNASWAMY YELESWARAM
Street: 99 High Street, Suite 2100
City: Boston
State / country code: MA
Postal code: 02110

Prior-sale reporting

Nothing to report for the preceding three months: N

Remarks

The securities to be sold were acquired upon the vesting of founders shares during the period of 6/09/2024 through 8/20/2024

Notice signature

Notice date: 08/24/2026
Signed: /s/ Krishnaswamy Yeleswaram
Plan adoption dates: 12/10/2025

Company context

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

Current securities

RAPPNASDAQ · EQUITY · Current

Get the free weekly BCS email.